Kajian Repurposing Drug sebagai Prioritas Metode Pengembangan Obat

Rosa Adelina

Kajian Repurposing Drug sebagai Prioritas Metode Pengembangan Obat

Rosa Adelina

Abstract

COVID-19 pandemic happened 100 years after Spanish Flu which caused high mortality in the world. It raised awareness about the importance to have drug development strategy acceleration. One of the drug development methods is drug repurposing. The urge for a deeper review of this method will be discussed in this article. The research method was reviewer literature that describes the terminology, the use of drug repurposing in cancer, COVID-19 and other diseases therapies and also the advantages to using drug repurposing method in drug development. The results showed some similar terms in drug repurposings such as drug repositioning, drug reprofiling, and drug rediscovery that makes drug repurposing preferred for old drug in new indication. Drug repurposing for anticancer are thiotepa, doxorubicine, gemcitabine, and raloxifene. Drug repurposing for COVID-19 are dexamethasone, methylprednisolone, sarilumab, heparine, enoxasaparine, rivaroxabane, and fondaparinux. The other uses are zidovudine, minoxidil, sildenafile, rituximab, and ketoconazole. The advantages from this method are higher time and cost-efficiency. Hesitance, drug therapy with drug repurposing method should be a priority for drug development nowadays.

Keywords

drug repurposing; drug development; review; application in drug therapy

References

Adelina, R. (2021) ‘Akselerasi Pengembangan Obat Dunia dan Indonesia Akibat Pandemi COVID-19’ in Subchi, I. et al Pandemi di Berbagai Perspektif. Rajagrafindo Persada, pp. 89-112.

Aggarwal, S., Verma, S. S., and Gupta, S. C. (2021) ‘Drug repurposing for breast cancer therapy: Old weapon for new battle’ in seminars in cancer biology (Vol. 68, pp. 8-20). Academic Press. https://doi.org/10.1016/j.semcancer.2019.09.012

Aghila Rani, K. G., et al. (2021) ‘Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges’, Expert Opinion on Drug Discovery, 16(4), 365-371. https://doi.org/10.1080/17460441.2021.1854221

Al-Khafaji, K., Al-Duhaidahawi, D., and Taskin Tok, T. (2021) ‘Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2’, Journal of Biomolecular Structure and Dynamics, 39(9), 3387-3395. https://doi.org/10.1080/07391102.2020.1764392

Allarakhia, M. (2013) ‘Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases’, Drug Design, Development and Therapy, 7, 753. https://dx.doi.org/10.2147%2FDDDT.S46289

Alvarellos, M. L., et al. (2014) ‘PharmGKB summary: gemcitabine pathway’, Pharmacogenetics and genomics, 24(11), 564. https://dx.doi.org/10.1097%2FFPC.0000000000000086

Badan Pengawasan Obat dan Makanan Republik Indonesia (2021) Informatorium Obat COVID-19 di Indonesia Edisi 3. Indonesia: internet. Available at: https://jdih.pom.go.id/view/slide/1309/HK.02.02.1.2.10.21.414%20TAHUN%202021/2021

Binaschi, M., et al. (2001) ‘Anthracyclines: selected new developments’, Current Medicinal Chemistry-Anti-Cancer Agents, 1(2), 113-130. https://doi.org/10.2174/1568011013354723

Bloom, D. E., and Cadarette, D. (2019) ‘Infectious disease threats in the twenty-first century: strengthening the global response’, Frontiers in immunology, 10, 549. https://doi.org/10.3389/fimmu.2019.00549

Dotolo, S., et al. (2021) ‘A review on drug repurposing applicable to COVID-19’, Briefings in Bioinformatics, 22(2), 726-741. https://doi.org/10.1093/bib/bbaa288

Global Change Data Lab (2022) Indonesia: Coronavirus Pandemic Country Profile. Available at: https://ourworldindata.org/coronavirus/country/indonesia#how-many-tests-are-performed-each-day

Gupta, S. C., Sung, B., Prasad, S., Webb, L. J., & Aggarwal, B. B. (2013). Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends in pharmacological sciences, 34(9), 508-517.

Kim, K. W., et al. (2016) Cancer Drug Discovery. Berlin/Heidelberg, Germany: Springer.

Langedijk, J., et al. (2015) ‘Drug repositioning and repurposing: terminology and definitions in literature’, Drug discovery today, 20(8), 1027-1034. https://doi.org/10.1016/j.drudis.2015.05.001

Lee, K., et al. (2017) ‘Gemcitabine, a broad-spectrum antiviral drug, suppresses enterovirus infections through innate immunity induced by the inhibition of pyrimidine biosynthesis and nucleotide depletion, Oncotarget, 8(70), 115315. https://dx.doi.org/10.18632%2Foncotarget.23258

Li, J., et al. (2016) ‘A survey of current trends in computational drug repositioning’ Briefings in Bioinformatics, 17(1), 2-12. https://doi.org/10.1093/bib/bbv020

Neuberger, A., Oraiopoulos, N., and Drakeman, D. L. (2019) ‘Renovation as innovation: is repurposing the future of drug discovery research?’, Drug discovery today, 24(1), 1-3. https://doi.org/10.1016/j.drudis.2018.06.012

Provinciali, N., et al. (2016) ‘Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women’, Expert review of clinical pharmacology, 9(10), 1263-1272. https://doi.org/10.1080/17512433.2016.1231575

Rahayu, S., Adelina, R., dan Wicaksono, A. J. (2020). Kebijakan dan Inovasi Saat Pandemi Covid-19 di Indonesia. Yogyakarta: Pena Persada.

Shim, J. S., and Liu, J. O. (2014) ‘Recent advances in drug repositioning for the discovery of new anticancer drugs’, International journal of biological sciences, 10(7), 654. https://dx.doi.org/10.7150%2Fijbs.9224

Zheng, Z. Y., et al. (2018) ‘Induction of N-Ras degradation by flunarizine-mediated autophagy’, Scientific reports, 8(1), 1-7. https://doi.org/10.1038/s41598-018-35237-2

Zilhadia (2020) ‘Kejadian Luar Biasa COVID-19, Sebuah Tinjauan Literatur Secara Singkat’, Pharmaceutical and Biomedical Sciences Journal, 2 (1), 19-26.

Zou, D., Ma, L., Yu, J., and Zhang, Z. (2015) ‘Biological databases for human research’, Genomics, proteomics and bioinformatics, 13(1), 55-63. https://doi.org/10.1016/j.gpb.2015.01.006

Full Text: PDF

DOI: 10.15408/pbsj.v3i2.24345